Several media have published an interview with Patrick Aloy, head of the Structural Bioinformatics and Network Biology Lab at IRB Barcelona, in which he talks about a study being done by scientists at the University of California. This study analyses the physical interactions of the coronavirus in order to understand how this virus “sequesters” our proteins to ensure its survival. This research aims to find drugs that can act against these proteins. In this regard, the researchers at the University of California have found 70 compounds, including around 30 drugs authorized by the US Food and Drug Agency(FDA).
Aloy explains that the strategy to look for pharmacological targets among the human proteins with which the virus interacts is pertinent since, among other factors, the virus has very few of its own proteins. However, he goes on to say that there is still a long way to go before a cure can be found.
Link to: Agencia SINC
Link to: Voz Populi
Link to: iLeon
Link to: Herencia genética y
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).